, Volume 13, Issue 1, pp 99-106
Date: 04 May 2007

Medication adherence in heart failure

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Non-adherence with medical regimens in heart failure is a significant challenge and serves as a major reason that favorable outcomes associated with various therapies evaluated in clinical trials have not translated to the so-called real-world setting. Non-adherence has complex influences and is clearly associated with poorer outcomes. The approaches that are used or have been proposed to improve drug-taking behavior, such as in-hospital initiation of therapy, simplification of dosing regimens through adoption of combination and long-acting formulations, and improvements in provider–patient communication, are reviewed.

Financial Disclosures (disease state, past 5 years, any amount): Paul J. Hauptman, MD, reported that he has received research grants from Abbott Laboratories, Novacardia, Acorn Cardiovascular, Orqis Medical, Novartis, Otsuka, GlaxoSmithKline, and the National Institutes of Health. He was on the Steering Committee of the CASPER Trial, which is designed to examine the impact of a once-daily formulation of carvedilol on compliance. He is/has been on the speaker’s bureau or has received honoraria in the past 5 years from GlaxoSmithKline, King Pharmaceuticals, AstraZeneca, and Johnson & Johnson, and is or has been a consultant for GlaxoSmithKline, Otsuka, BioControl Medical, and Novacardia.